April 2020
View this email in your browser

Alberta Biosimilar Initiative Update

For adult patients enrolled in an Alberta government sponsored drug plan who are receiving Remicade for plaque psoriasis or psoriatic arthritis or Enbrel for psoriatic arthritis, please note the following update and attached notification letter regarding the Alberta Biosimilar Initiative.

The switching requirement of the Biosimilar Initiative for these patients is postponed from July 1, 2020 to January 15, 2021 due to the COVID-19 pandemic.
Updated information for patients and prescribers will be posted on the Alberta Blue Cross website at the links below:
For patients:
For prescribers:

For more information see this notification letter.
We continue to wish our community well during these trying times.

If you have any general questions or concerns about COVID-19 and psoriasis that you would like us to look into, or if you've encountered any issues with accessing your treatments due to the COVID-19 pandemic, please email us at or share your question by clicking here.

If you are experiencing issues with accessing your treatment, we also invite you to complete this short survey by our friends at the Canadian Skin Patient Alliance:

On our site, CPN continues to post links to reputable resources to keep our members and community connected to current information.

These include links to health information and guidance on restrictions and practices across Canada such as:


Public Health Agency of Canada
Provincial/territorial governments
Canadian Dermatology Association
Canadian Rheumatology Association
Canadian Skin Patient Alliance Covid-19 FAQ

As well as info about taking care of your mental health during the pandemic:
Canadian Mental Health Association

As many people are seeing their jobs affected these days, there may be concerns about disrupted access to insurance for treatments. Check out this Understanding Access Fact Sheet as a reminder of ways people may access treatments for psoriasis and psoriatic arthritis in Canada.

Reminder: Canadian Pain Task Force consultation

We know that pain is a major problem for many people who live with psoriatic disease.
For this reason, CPN is sharing information about a consultation being led by the Canadian Pain Task Force to help the Government of Canada better understand and address the needs of the millions of Canadians who live with pain.

This consultation has been extended to May 29, 2020. Share your input directly online by May 29, 2020.

If you would like to share your input with CPN to inform our submission to the task force, please fill out this anonymous questionnaire by May 20th.
If you would like to share your story about living with psoriasis or
psoriatic arthritis, let's chat!

Send us a message at:
Copyright © 2020 Canadian Psoriasis Network. All rights reserved.

Our mailing address is:
PO Box 8706, Ottawa ON. K1G 3J1

unsubscribe from this list    update subscription preferences 

This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
Canadian Psoriasis Network · 328 Bartlett Ave · Suite 809 · Toronto, Ontario M6H 3G7 · Canada

Email Marketing Powered by Mailchimp